Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
30.37
-0.28 (-0.91%)
Nov 11, 2026, 2:15 PM EST - Market open
Celldex Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Celldex Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $64. The average 1-year stock price forecast is 110.73% higher than the current stock price, while the lowest is $29 (-4.51%) and the highest is $100 (+229.27%).
Price Target: $64 (+110.73%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 13 | 12 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $57 → $61 | Buy | Reiterates | $57 → $61 | +100.86% | Nov 9, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $60 → $68 | Buy | Reiterates | $60 → $68 | +123.91% | Nov 9, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $28 → $29 | Hold | Maintains | $28 → $29 | -4.51% | Nov 6, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $72 | Buy | Maintains | $72 | +137.08% | Nov 6, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $68 | Buy | Reiterates | $68 | +123.91% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
1.59M
from 1.55M
Increased by 2.93%
Revenue Next Year
9.31M
from 1.59M
Increased by 485.55%
EPS This Year
-4.13
from -3.90
EPS Next Year
-4.21
from -4.13
EPS and Forward PE are based on non-GAAP adjusted numbers.